{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:13:53Z","timestamp":1789614833930,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DKFZ-Bayer Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma is a highly aggressive brain tumor for which there is no cure. The metabolic enzyme 6-Phosphofructo-2-Kinase\/Fructose-2,6-Biphosphatase 4 (PFKFB4) is essential for glioblastoma stem-like cell (GSC) survival but its mode of action is unclear. Understanding the role of PFKFB4 in tumor cell survival could allow it to be leveraged in a cancer therapy. Here, we show the importance of PFKFB4 for glioblastoma growth in vivo in an orthotopic patient derived mouse model. In an evaluation of patient tumor samples of different cancer entities, PFKFB4 protein was found to be overexpressed in prostate, lung, colon, mammary and squamous cell carcinoma, with expression level correlating with tumor grade. Gene expression profiling in\n                    <jats:italic>PFKFB4<\/jats:italic>\n                    -silenced GSCs revealed a downregulation of hypoxia related genes and Western blot analysis confirmed a dramatic reduction of HIF (hypoxia inducible factor) protein levels. Through mass spectrometric analysis of immunoprecipitated PFKFB4, we identified the ubiquitin E3 ligase, F-box only protein 28 (FBXO28), as a new interaction partner of PFKFB4. We show that PFKFB4 regulates the ubiquitylation and subsequent proteasomal degradation of HIF-1\u03b1, which is mediated by the ubiquitin ligase activity of FBXO28. This newly discovered function of PFKFB4, coupled with its cancer specificity, provides a new strategy for inhibiting HIF-1\u03b1 in cancer cells.\n                  <\/jats:p>","DOI":"10.1038\/s41389-022-00433-3","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T07:05:40Z","timestamp":1663398340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["PFKFB4 interacts with FBXO28 to promote HIF-1\u03b1 signaling in glioblastoma"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8946-3284","authenticated-orcid":false,"given":"Emma","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Balss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Bethke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Christen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Schn\u00f6lzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N. C.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Habel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tessmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"G\u00f6ttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Capper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Herold-Mende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Maria","family":"Fendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9046-4893","authenticated-orcid":false,"given":"Violaine","family":"Goidts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"433_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl J Med. 2005;352:987\u201396.","journal-title":"N. Engl J Med"},{"key":"433_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007;114:97\u2013109.","journal-title":"Acta Neuropathologica"},{"key":"433_CR3","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821\u20138.","journal-title":"Cancer Res"},{"key":"433_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396\u2013401.","journal-title":"Nature"},{"key":"433_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","volume":"6","author":"BC Prager","year":"2020","unstructured":"Prager BC, Bhargava S, Mahadev V, Hubert CG, Rich JN. Glioblastoma Stem cells: Driving Resilience through Chaos. Trends Cancer. 2020;6:223\u201335.","journal-title":"Trends Cancer"},{"key":"433_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756\u201360.","journal-title":"Nature"},{"key":"433_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/07357900801904140","volume":"26","author":"A Shervington","year":"2008","unstructured":"Shervington A, Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Investig. 2008;26:535\u201342.","journal-title":"Cancer Investig"},{"key":"433_CR8","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1158\/0008-5472.CAN-04-1364","volume":"64","author":"R Galli","year":"2004","unstructured":"Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011\u201321.","journal-title":"Cancer Res"},{"key":"433_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molmet.2018.11.013","volume":"20","author":"M Yi","year":"2019","unstructured":"Yi M, Ban Y, Tan Y, Xiong W, Li G, Xiang B. 6-Phosphofructo-2-kinase\/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer. Mol Metab. 2019;20:1\u201313.","journal-title":"Mol Metab"},{"key":"433_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/biof.5520100101","volume":"10","author":"DA Okar","year":"1999","unstructured":"Okar DA, Lange AJ. Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes. Biofactors 1999;10:1\u201314.","journal-title":"Biofactors"},{"key":"433_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2049-3002-1-8","volume":"1","author":"S Ros","year":"2013","unstructured":"Ros S, Schulze A. Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase\/fructose 2,6-bisphosphatases in cancer metabolism. Cancer Metab. 2013;1:8.","journal-title":"Cancer Metab"},{"key":"433_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.biochi.2005.04.007","volume":"87","author":"OH Minchenko","year":"2005","unstructured":"Minchenko OH, Ochiai A, Opentanova IL, Ogura T, Minchenko DO, Caro J, et al. Overexpression of 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochimie 2005;87:1005\u201310.","journal-title":"Biochimie"},{"key":"433_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.urolonc.2010.08.018","volume":"30","author":"SJ Yun","year":"2012","unstructured":"Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, et al. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer. Urol Oncol. 2012;30:893\u20139.","journal-title":"Urol Oncol"},{"key":"433_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13046-021-02103-5","volume":"40","author":"C Feng","year":"2021","unstructured":"Feng C, Li Y, Li K, Lyu Y, Zhu W, Jiang H, et al. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance. J Exp Clin Cancer Res. 2021;40:308.","journal-title":"J Exp Clin Cancer Res"},{"key":"433_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/jnen\/nlz067","volume":"78","author":"R Kessler","year":"2019","unstructured":"Kessler R, Fleischer M, Springsguth C, Bigl M, Warnke JP, Eschrich K. Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype). J Neuropathol Exp Neurol. 2019;78:865\u201370.","journal-title":"J Neuropathol Exp Neurol"},{"key":"433_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/2159-8290.CD-11-0234","volume":"2","author":"S Ros","year":"2012","unstructured":"Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, et al. Functional metabolic screen identifies 6-phosphofructo-2-kinase\/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov. 2012;2:328\u201343.","journal-title":"Cancer Discov"},{"key":"433_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-018-0018-1","volume":"556","author":"S Dasgupta","year":"2018","unstructured":"Dasgupta S, Rajapakshe K, Zhu B, Nikolai BC, Yi P, Putluri N, et al. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 2018;556:249\u201354.","journal-title":"Nature"},{"key":"433_CR18","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1038\/onc.2011.490","volume":"31","author":"V Goidts","year":"2012","unstructured":"Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, et al. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 2012;31:3235\u201343.","journal-title":"Oncogene"},{"key":"433_CR19","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jocn.2007.07.080","volume":"15","author":"MY Kaynar","year":"2008","unstructured":"Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, et al. Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci. 2008;15:1036\u201342.","journal-title":"J Clin Neurosci"},{"key":"433_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1101\/gad.14.1.34","volume":"14","author":"R Ravi","year":"2000","unstructured":"Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000;14:34\u201344.","journal-title":"Genes Dev"},{"key":"433_CR21","first-page":"1541","volume":"60","author":"H Zhong","year":"2000","unstructured":"Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60:1541\u20135.","journal-title":"Cancer Res"},{"key":"433_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/onc.2009.441","volume":"29","author":"GL Semenza","year":"2010","unstructured":"Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625\u201334.","journal-title":"Oncogene"},{"key":"433_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1021\/mp800192d","volume":"6","author":"XL Wang","year":"2009","unstructured":"Wang XL, Xu R, Wu X, Gillespie D, Jensen R, Lu ZR. Targeted systemic delivery of a therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice. Mol Pharm. 2009;6:738\u201346.","journal-title":"Mol Pharm"},{"key":"433_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2018.00249","volume":"8","author":"A Lo Dico","year":"2018","unstructured":"Lo Dico A, Martelli C, Diceglie C, Lucignani G, Ottobrini L. Hypoxia-Inducible Factor-1alpha Activity as a Switch for Glioblastoma Responsiveness to Temozolomide. Front Oncol. 2018;8:249.","journal-title":"Front Oncol"},{"key":"433_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-pharmtox-010818-021637","volume":"59","author":"GL Semenza","year":"2019","unstructured":"Semenza GL. Pharmacologic Targeting of Hypoxia-Inducible Factors. Annu Rev Pharm Toxicol. 2019;59:379\u2013403.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"433_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/15384101.2016.1241929","volume":"16","author":"L Zhang","year":"2017","unstructured":"Zhang L, Xu L, Zhang F, Vlashi E. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017;16:737\u201345.","journal-title":"Cell Cycle"},{"key":"433_CR27","doi-asserted-by":"publisher","first-page":"15215","DOI":"10.1074\/jbc.M511408200","volume":"281","author":"GP Elvidge","year":"2006","unstructured":"Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem. 2006;281:15215\u201326.","journal-title":"J Biol Chem"},{"key":"433_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2010.05.024","volume":"18","author":"J Qi","year":"2010","unstructured":"Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 2010;18:23\u201338.","journal-title":"Cancer Cell"},{"key":"433_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462\u201377.","journal-title":"Cell"},{"key":"433_CR30","doi-asserted-by":"publisher","first-page":"e0149492","DOI":"10.1371\/journal.pone.0149492","volume":"11","author":"LM Langan","year":"2016","unstructured":"Langan LM, Dodd NJ, Owen SF, Purcell WM, Jackson SK, Jha AN. Direct Measurements of Oxygen Gradients in Spheroid Culture System Using Electron Parametric Resonance Oximetry. PLoS One. 2016;11:e0149492.","journal-title":"PLoS One"},{"key":"433_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.freeradbiomed.2017.10.003","volume":"113","author":"TL Place","year":"2017","unstructured":"Place TL, Domann FE, Case AJ. Limitations of oxygen delivery to cells in culture: An underappreciated problem in basic and translational research. Free Radic Biol Med. 2017;113:311\u201322.","journal-title":"Free Radic Biol Med"},{"key":"433_CR32","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.18632\/oncotarget.4534","volume":"6","author":"J Chesney","year":"2015","unstructured":"Chesney J, Clark J, Lanceta L, Trent JO, Telang S. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor. Oncotarget 2015;6:18001\u201311.","journal-title":"Oncotarget"},{"key":"433_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/emmm.201202341","volume":"5","author":"D Cepeda","year":"2013","unstructured":"Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, et al. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med. 2013;5:1067\u201386.","journal-title":"EMBO Mol Med"},{"key":"433_CR34","doi-asserted-by":"publisher","first-page":"14094","DOI":"10.1073\/pnas.0804455105","volume":"105","author":"E Fredlund","year":"2008","unstructured":"Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA. 2008;105:14094\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"433_CR35","doi-asserted-by":"publisher","first-page":"9065","DOI":"10.1158\/0008-5472.CAN-09-2307","volume":"69","author":"LA Gravendeel","year":"2009","unstructured":"Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69:9065\u201372.","journal-title":"Cancer Res"},{"key":"433_CR36","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","volume":"19","author":"K Tanimoto","year":"2000","unstructured":"Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000;19:4298\u2013309.","journal-title":"EMBO J"},{"key":"433_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-335","volume":"8","author":"A Daponte","year":"2008","unstructured":"Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, et al. Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer. 2008;8:335.","journal-title":"BMC Cancer"},{"key":"433_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-320","volume":"8","author":"N Simiantonaki","year":"2008","unstructured":"Simiantonaki N, Taxeidis M, Jayasinghe C, Kurzik-Dumke U, Kirkpatrick CJ. Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer. 2008;8:320.","journal-title":"BMC Cancer"},{"key":"433_CR39","first-page":"5280","volume":"58","author":"H Zhong","year":"1998","unstructured":"Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, et al. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998;58:5280\u20134.","journal-title":"Cancer Res"},{"key":"433_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fcell.2017.00043","volume":"5","author":"M Strickland","year":"2017","unstructured":"Strickland M, Stoll EA. Metabolic Reprogramming in Glioma. Front Cell Dev Biol. 2017;5:43.","journal-title":"Front Cell Dev Biol"},{"key":"433_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ccell.2014.09.013","volume":"26","author":"RJ Davis","year":"2014","unstructured":"Davis RJ, Welcker M, Clurman BE. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell. 2014;26:455\u201364.","journal-title":"Cancer Cell"},{"key":"433_CR42","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1002\/jcb.23321","volume":"112","author":"JM Cassavaugh","year":"2011","unstructured":"Cassavaugh JM, Hale SA, Wellman TL, Howe AK, Wong C, Lounsbury KM. Negative regulation of HIF-1alpha by an FBW7-mediated degradation pathway during hypoxia. J Cell Biochem. 2011;112:3882\u201390.","journal-title":"J Cell Biochem"},{"key":"433_CR43","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.18632\/oncotarget.2213","volume":"5","author":"J Chesney","year":"2014","unstructured":"Chesney J, Clark J, Klarer AC, Imbert-Fernandez Y, Lane AN, Telang S. Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. Oncotarget 2014;5:6670\u201386.","journal-title":"Oncotarget"},{"key":"433_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1101\/gad.12.2.149","volume":"12","author":"NV Iyer","year":"1998","unstructured":"Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12:149\u201362.","journal-title":"Genes Dev"},{"key":"433_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bbrc.2016.05.026","volume":"476","author":"H Zhang","year":"2016","unstructured":"Zhang H, Lu C, Fang M, Yan W, Chen M, Ji Y, et al. HIF-1alpha activates hypoxia-induced PFKFB4 expression in human bladder cancer cells. Biochem Biophys Res Commun. 2016;476:146\u201352.","journal-title":"Biochem Biophys Res Commun"},{"key":"433_CR46","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/cdd.2011.95","volume":"19","author":"L Qiang","year":"2012","unstructured":"Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang YJ, et al. HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ. 2012;19:284\u201394.","journal-title":"Cell Death Differ"},{"key":"433_CR47","first-page":"199","volume":"3","author":"LM Nusblat","year":"2020","unstructured":"Nusblat LM, Tanna S, Roth CM. Gene silencing of HIF-2alpha disrupts glioblastoma stem cell phenotype. Cancer Drug Resist. 2020;3:199\u2013208.","journal-title":"Cancer Drug Resist"},{"key":"433_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72290-2","volume":"10","author":"JJ Renfrow","year":"2020","unstructured":"Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, et al. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020;10:15195.","journal-title":"Sci Rep"},{"key":"433_CR49","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud GN, Li W. HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378\u201389.","journal-title":"Acta Pharm Sin B."},{"key":"433_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0752-z","volume":"21","author":"J Fallah","year":"2019","unstructured":"Fallah J, Rini BI. HIF Inhibitors: Status of Current Clinical Development. Curr Oncol Rep. 2019;21:6.","journal-title":"Curr Oncol Rep"},{"key":"433_CR51","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1158\/1078-0432.CCR-09-1800","volume":"16","author":"B Campos","year":"2010","unstructured":"Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res. 2010;16:2715\u201328.","journal-title":"Clin Cancer Res"},{"key":"433_CR52","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1158\/1078-0432.CCR-09-0695","volume":"15","author":"A Ernst","year":"2009","unstructured":"Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res. 2009;15:6541\u201350.","journal-title":"Clin Cancer Res"},{"key":"433_CR53","doi-asserted-by":"publisher","first-page":"11033","DOI":"10.1093\/nar\/gkw880","volume":"44","author":"JA Vizcaino","year":"2016","unstructured":"Vizcaino JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44:11033.","journal-title":"Nucleic Acids Res"},{"key":"433_CR54","doi-asserted-by":"publisher","first-page":"268.","DOI":"10.3390\/ijms22010268","volume":"22","author":"A Albanese","year":"2021","unstructured":"Albanese A, Daly LA, Mennerich D, Kietzmann T, See V. The Role of Hypoxia-Inducible Factor Post-Translational Modifications in Regulating Its Localisation, Stability, and Activity. Int J Mol Sci. 2021;22:268.","journal-title":"Int J Mol Sci"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-022-00433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-022-00433-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-022-00433-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T12:20:12Z","timestamp":1663417212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-022-00433-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1038\/s41389-022-00433-3","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DKFZ filed the patent application EP19701524.1 based on the results of this study and VG, EP, JB ad FB are listed as inventor. The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}